Prothena Corporation PLC
PRTA8.910USD
+0.560+6.71%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
479.63MMarket Cap
LossP/E TTM
More Details of Prothena Corporation PLC Company
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Prothena Corporation PLC Info
Ticker SymbolPRTA
Company nameProthena Corporation PLC
IPO dateDec 21, 2012
CEOKinney (Gene G)
Number of employees163
Security typeOrdinary Share
Fiscal year-endDec 21
Address77 Sir John Rogerson's Quay, Block C
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal codeD02 VK60
Phone35312362500
Websitehttps://www.prothena.com/
Ticker SymbolPRTA
IPO dateDec 21, 2012
CEOKinney (Gene G)
Company Executives of Prothena Corporation PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
--
--
Mr. Tran B. Nguyen
Mr. Tran B. Nguyen
Chief Financial Officer, Chief Strategy Officer
Chief Financial Officer, Chief Strategy Officer
--
--
Dr. Gene G. Kinney, Ph.D.
Dr. Gene G. Kinney, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Karin L. Walker, CPA
Ms. Karin L. Walker, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Paula K. Cobb
Ms. Paula K. Cobb
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.68%
Scully (William P)
9.81%
Fennell (Todd W.)
8.35%
BlackRock Institutional Trust Company, N.A.
5.51%
The Vanguard Group, Inc.
3.98%
Other
57.67%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.68%
Scully (William P)
9.81%
Fennell (Todd W.)
8.35%
BlackRock Institutional Trust Company, N.A.
5.51%
The Vanguard Group, Inc.
3.98%
Other
57.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.48%
Hedge Fund
23.91%
Individual Investor
19.39%
Investment Advisor/Hedge Fund
16.22%
Research Firm
4.34%
Pension Fund
0.17%
Bank and Trust
0.16%
Sovereign Wealth Fund
0.11%
Venture Capital
0.03%
Other
0.19%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
438
43.29M
80.42%
-20.02M
2025Q3
450
41.85M
77.74%
-15.20M
2025Q2
460
51.33M
95.35%
-19.91M
2025Q1
472
64.29M
119.45%
-7.39M
2024Q4
479
65.24M
121.19%
+239.99K
2024Q3
476
59.39M
110.43%
-5.39M
2024Q2
479
58.48M
108.76%
-4.67M
2024Q1
472
60.86M
113.29%
-264.94K
2023Q4
474
56.64M
105.77%
-2.21M
2023Q3
476
55.90M
104.65%
-1.73M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
7.90M
14.68%
--
--
Sep 30, 2025
Scully (William P)
5.28M
9.81%
-70.00K
-1.31%
Sep 30, 2025
Fennell (Todd W.)
4.50M
8.35%
+145.00K
+3.33%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.97M
5.51%
-153.69K
-4.92%
Sep 30, 2025
The Vanguard Group, Inc.
2.05M
3.81%
-117.67K
-5.43%
Sep 30, 2025
Armistice Capital LLC
1.82M
3.39%
-412.00K
-18.43%
Sep 30, 2025
Rubric Capital Management LP
1.54M
2.86%
+1.54M
--
Sep 30, 2025
Adar1 Capital Management LLC
1.47M
2.73%
-1.91M
-56.47%
Sep 30, 2025
Palo Alto Investors LP
1.32M
2.46%
+49.27K
+3.87%
Sep 30, 2025
D. E. Shaw & Co., L.P.
1.32M
2.44%
+923.92K
+236.00%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.44%
iShares Neuroscience and Healthcare ETF
0.78%
Invesco NASDAQ Future Gen 200 ETF
0.7%
Federated Hermes MDT Small Cap Core ETF
0.62%
ALPS Medical Breakthroughs ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.06%
Avantis US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
WisdomTree US SmallCap Fund
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.44%
iShares Neuroscience and Healthcare ETF
Proportion0.78%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
Federated Hermes MDT Small Cap Core ETF
Proportion0.62%
ALPS Medical Breakthroughs ETF
Proportion0.24%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
Avantis US Small Cap Equity ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.04%
WisdomTree US SmallCap Fund
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
